FFAR1; FFAR4; | |
RECQL; GLO1; HPGD; ALOX12; AKR1B1; HSD17B10; NOX4; ALOX15; TNKS; PARP1; TNKS2; POLB; CD38; | |
FLT3; GSK3B; | |
CA2; CA12; CA7; CA4; | |
PPARA; PPARD; PPARG; | |
ALOX5; MAOA; XDH; | |
KDM4E; | |
MMP9; MMP12; MMP2; | |
TLR2; | |
HIF1A; TP53; | |
ABCG2; | |
LMNA; FABP5; FABP2; FABP4; FABP3; APP; TTR; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.590E-09 | 2.663E-06 | CA12, CA2, CA4, CA7, GLO1, MMP12, MMP2, MMP9, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.117E-08 | 1.660E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.480E-08 | 2.057E-05 | ALOX12, ALOX15, ALOX5, HPGD |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.117E-07 | 4.053E-05 | ALOX12, ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, XDH |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.786E-07 | 6.077E-05 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.748E-07 | 1.074E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.224E-07 | 2.363E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.601E-06 | 3.594E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.711E-06 | 3.803E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 3.190E-06 | 6.492E-04 | AKR1B1, CD38, CYP1A1, CYP1B1, FFAR1, FFAR4, HIF1A, PPARD, TTR |
BP | GO:0008152; metabolic process | GO:1901564; organonitrogen compound metabolic process | 3.469E-06 | 6.872E-04 | ABCG2, AKR1B1, APP, CD38, CYP1A1, CYP1A2, FLT3, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, MAOA, MMP12, MMP2, MMP9, NOX4, PARP1, POLB, PPARA, PPARD, PPARG, TLR2, TNKS, TNKS2, TP53, TTR, XDH |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.888E-06 | 7.299E-04 | CA12, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.260E-06 | 7.862E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.942E-06 | 8.750E-04 | AKR1B1, ALOX12, CD38, FFAR4, GLO1, GSK3B, HIF1A, LMNA, MMP9, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.795E-06 | 9.782E-04 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.795E-06 | 9.782E-04 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 8.899E-06 | 1.414E-03 | NOX4, PARP1, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 8.964E-06 | 1.414E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.736E-05 | 2.446E-03 | APP, TLR2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.736E-05 | 2.446E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.741E-05 | 2.446E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.736E-05 | 2.446E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.736E-05 | 2.446E-03 | ALOX12, ALOX15 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.013E-05 | 2.792E-03 | HPGD, MMP2, MMP9 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.107E-05 | 2.904E-03 | FABP3, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 2.160E-05 | 2.939E-03 | FABP3, PARP1, PPARA, PPARG, TLR2 |
BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 2.235E-05 | 3.023E-03 | CD38, FFAR1, HIF1A, PPARD |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.311E-05 | 3.087E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.311E-05 | 3.087E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.636E-05 | 3.397E-03 | CYP1A1, CYP1A2, PPARG |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.848E-05 | 3.648E-03 | AKR1B1, APP, CYP1A1, CYP1A2, CYP1B1, PPARD |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.991E-05 | 3.764E-03 | HIF1A, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.466E-05 | 4.086E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 3.466E-05 | 4.086E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.466E-05 | 4.086E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 3.375E-05 | 4.086E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 3.655E-05 | 4.256E-03 | ALOX15, PPARA, PPARD, TP53 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 3.791E-05 | 4.344E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 3.791E-05 | 4.344E-03 | APP, GSK3B, PARP1 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 4.081E-05 | 4.652E-03 | ABCG2, AKR1B1, APP, CA4, CD38, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, LMNA, MAOA, MMP12, MMP2, NOX4, PARP1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, TLR2, TNKS, TNKS2, TP53, XDH |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.249E-05 | 4.794E-03 | FABP3, FFAR1, PPARG, TLR2 |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 4.923E-05 | 5.255E-03 | AKR1B1, CYP1A1, CYP1B1, HPGD, POLB, TLR2, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 5.340E-05 | 5.617E-03 | ALOX12, APP, CD38, FFAR4, GSK3B, HIF1A, LMNA, PPARD, PPARG, TLR2, XDH |
BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 5.506E-05 | 5.737E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 5.645E-05 | 5.853E-03 | HIF1A, MMP12, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.768E-05 | 5.869E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 5.768E-05 | 5.869E-03 | PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 6.744E-05 | 6.645E-03 | CYP1A1, CYP1B1, PPARD, TTR |
BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 7.043E-05 | 6.816E-03 | AKR1B1, CD38, PARP1, PPARG, TLR2 |
BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 8.638E-05 | 8.039E-03 | PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 8.638E-05 | 8.039E-03 | PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0070212; protein poly-ADP-ribosylation | 8.638E-05 | 8.039E-03 | PARP1, TNKS |
MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 8.638E-05 | 8.039E-03 | FABP3, PPARG |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 9.636E-05 | 8.779E-03 | ABCG2, APP, CD38, FLT3, HPGD, MMP9, PARP1, PPARG, SMN1, SMN2, TP53, TTR, XDH |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 9.785E-05 | 8.841E-03 | CYP1B1, GSK3B, HPGD, MMP9, NOX4, PPARG, TP53, XDH |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.073E-04 | 9.382E-03 | MMP2, MMP9, PPARD |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.399E-10 | 3.167E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.589E-06 | 1.184E-04 | GSK3B; FLT3; MMP2; PPARG; HIF1A; TP53; MMP9; PPARD |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.299E-06 | 1.012E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.229E-08 | 4.111E-06 | CA12; CA2; CA4; CA7 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.401E-06 | 1.690E-04 | APP; MAOA; ALOX5; ALOX15; ALOX12 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.112E-04 | 1.786E-03 | MMP2; TP53; HIF1A; MMP9; TLR2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.307E-05 | 1.189E-03 | HPGD; FLT3; PPARG; TP53; MMP9 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.218E-04 | 1.786E-03 | MMP2; MMP9; TP53 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.206E-04 | 2.912E-03 | ALOX5; CYP1A1; CYP1B1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.060E-04 | 4.944E-03 | MAOA; ALOX5; CYP1A2; ALOX15; CYP1A1; CD38; AKR1B1; ALOX12; HSD17B10; XDH |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.174E-04 | 4.591E-03 | ALOX5; ALOX15; ALOX12 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.428E-04 | 4.113E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.244E-04 | 4.944E-03 | FLT3; TP53; HIF1A |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.741E-04 | 5.932E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.457E-04 | 7.802E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.687E-03 | 1.713E-02 | GSK3B; TP53; HIF1A |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.346E-03 | 2.388E-02 | PARP1; LMNA; TP53 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.765E-03 | 2.259E-02 | GSK3B; PPARA; TP53 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 4.008E-03 | 2.300E-02 | GSK3B; TP53; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.886E-03 | 2.480E-02 | TP53; MMP9; TLR2 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 4.522E-03 | 2.388E-02 | GSK3B; TP53; PPARD |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.201E-03 | 3.375E-02 | APP; GSK3B; HSD17B10 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.188E-02 | 4.570E-02 | GSK3B; CD38; TP53 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.108E-03 | 1.464E-02 | PPARG; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.651E-03 | 3.252E-02 | GSK3B; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.946E-03 | 3.496E-02 | FLT3; PPARD |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 9.345E-03 | 3.979E-02 | GSK3B; TP53 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.108E-03 | 1.464E-02 | CYP1A2; ALOX15 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 7.415E-03 | 3.375E-02 | GSK3B; TP53 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.147E-02 | 4.570E-02 | MAOA; CYP1A2 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.023E-02 | 4.221E-02 | CYP1A2; CYP1A1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.325E-03 | 1.029E-02 | CA2; CA4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.212E-02 | 4.570E-02 | CA2; ABCG2 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.381E-05 | 1.184E-03 | CYP1A2; XDH |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.724E-03 | 1.713E-02 | POLB; PARP1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; MMP9; TLR2; MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; FLT3; FLT3; MMP9; TLR2; PARP1; MMP2; GSK3B; CD38; APP |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; MMP12 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; GSK3B; PPARG |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
C00-D49: Neoplasms | AML | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG |
C00-D49: Neoplasms | Glioma | C71 | APP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
NA: NA | GIST | NA | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR; APP |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; APP; PPARG; PPARG |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |